MedPath

Choline Source, Gut Microbiota and Trimethylamine-N-oxide Response

Not Applicable
Completed
Conditions
Metabolism
Interventions
Other: Water-soluble choline
Other: No choline control
Other: Fat-soluble choline
Registration Number
NCT04255368
Lead Sponsor
Utah State University
Brief Summary

The purpose of this research is to determine the production of trimethylamine-N-oxide (TMAO) from different forms of choline and whether this response is modified by the gut microbiota composition.

Detailed Description

The overall goal of this research is to identify dietary and physiological factors contributing to elevated levels of trimethylamine-N-oxide (TMAO), a choline-derived gut-microbiome-dependent metabolite that has been identified to increase cardiovascular disease risk. Our recent findings indicate that the gut microbiome may account for variations in TMAO levels, whereby those with a greater enrichment of Firmicutes to Bacteroidetes had elevated TMAO response to dietary precursor intake. However, the interaction between choline intake and gut microbiota composition as a determinant of interindividual variations in TMAO response has not been investigated. This study sought to i) compare plasma and urinary TMAO response after acute challenge containing different forms of choline; and ii) to determine the association between differences in TMAO response with differences in gut microbiota composition. To accomplish these objectives, a randomized, controlled cross-over study was conducted in healthy participants (n=41). The study incorporated three arms comprised of study meals containing (i) 600 mg choline as choline bitartrate; (ii) 600 mg choline as phosphatidylcholine; or (iii) no choline. Each meal was served with a bagel with margarine-butter spread and one cup of water, administered in a single day and separated by a 1-week washout period. Baseline blood sample was obtained by a phlebotomist using a standard venipuncture procedure, and participants collected their baseline urine sample. They also turned in a one-time self-collected baseline stool sample. Following the consumption of the study meal, serial blood samples were collected at 30 min and 1, 2, 4 and 6 h, and urine samples collected throughout the 6 h study period. At 4.5 h, participants were provided a fixed fruit snack (i.e., 2 single serving prepackaged applesauce) and water.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Healthy men and women of any race or ethnicity
  • Age 21-50 y
  • BMI 20-24.9 kg/m2 or BMI 30-39.9 kg/m2
Exclusion Criteria
  • Age > 50 y
  • BMI outside of the normal-weight or obese range (BMI < 20 kg/m2; BMI 25-29.9 kg/m2; or BMI > or = 40 kg/m2)
  • Pregnant or planning to become pregnant during the course of the study; currently breastfeeding (females)
  • Vegetarians
  • Smokers or recreational drug users
  • Individuals with gastrointestinal diseases or complaints, chronic illnesses or other metabolic diseases (including trimethylaminuria)
  • Individuals who have taken antibiotics within the past 2 months
  • Individuals who are not willing to discontinue pre- and probiotics and dietary supplements for the time leading up to 2 months before the study and during the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Water-soluble cholineWater-soluble cholineA breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as choline bitartrate; served with a bagel with margarine-butter spread and one cup of water.
No cholineNo choline controlA breakfast meal consisting of 1 cup of tomato soup containing no choline; served with a bagel with margarine-butter spread and one cup of water.
Fat-soluble cholineFat-soluble cholineA breakfast meal consisting of 1 cup of tomato soup containing 600 mg choline as phosphatidylcholine; served with a bagel with margarine-butter spread and one cup of water.
Primary Outcome Measures
NameTimeMethod
TMAO metabolite concentration changeUrine: study baseline, pooled 6 hours study period

Urinary TMAO metabolite response

Gut microbiome profileStool: one-time baseline

16S rRNA

Secondary Outcome Measures
NameTimeMethod
Phosphatidylcholine concentration changeBlood: study baseline, 30 minutes and 1 hour, 2 hours, 4 hours and 6 hours

Plasma phosphatidylcholine response

Inflammation and cardiovascular disease risk marker concentration changeBlood: study baseline to 6 hours

Plasma TNF-α and IL-6

One-carbon metabolite concentration changeUrine: study baseline, pooled 6 hours study period

Urinary choline metabolite response

Flavin monooxygenase 3 (FMO3) 472 G>A genotype variantBlood: study baseline

Genetic polymorphism

Trial Locations

Locations (1)

Center for Human Nutrition Studies Clinic, Utah State University

🇺🇸

Logan, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath